Gabapentin: A Ca2+ channel α2-δ ligand far beyond epilepsy therapy

Drugs of Today

Volumn 44, Issue 5, 2008, Pages 353-368

  Striano, Pasquale ^a,b   Striano, Salvatore ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CALCIUM CHANNEL L TYPE; CARBAMAZEPINE; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; MEMANTINE; OXCARBAZEPINE; TOPIRAMATE; VIGABATRIN; 4 AMINOBUTYRIC ACID; AMINE; ANTICONVULSIVE AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; LIGAND;

ABSENCE; AGGRESSION; AMINO ACID TRANSPORT; ANORGASMIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ATAXIA; CHOREOATHETOSIS; CHRONIC PAIN; COGNITION; CONGENITAL NYSTAGMUS; DIABETIC NEUROPATHY; DIARRHEA; DIPLOPIA; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; ECG ABNORMALITY; EJACULATION DISORDER; EPILEPSY; FATIGUE; FIBROMYALGIA; FOCAL EPILEPSY; FOOD; FOOD DRUG INTERACTION; GABAERGIC TRANSMISSION; GENERALIZED EPILEPSY; GERIATRIC PATIENT; HEADACHE; HEREDITARY SPINAL MUSCULAR ATROPHY; HOT FLUSH; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INCONTINENCE; IRRITABLE COLON; KIDNEY FAILURE; LEUKOPENIA; MIGRAINE; MONOTHERAPY; MOOD CHANGE; MULTIPLE SCLEROSIS; MYOCLONUS; MYOPATHY; NAUSEA; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; NYSTAGMUS; PAIN; PHARMACODYNAMICS; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PREGNANCY; PROPHYLAXIS; RASH; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPASTICITY; THROMBOCYTOPENIA; TREMOR; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN; ANIMAL; CLINICAL TRIAL; DRUG EFFECT;

AMINES; ANIMALS; ANTICONVULSANTS; CALCIUM CHANNELS, L-TYPE; CLINICAL TRIALS AS TOPIC; COGNITION; CYCLOHEXANECARBOXYLIC ACIDS; DIABETIC NEUROPATHIES; DRUG MONITORING; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIGANDS; NEURALGIA, POSTHERPETIC;

EID: 51649114823     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.5.1186403     Document Type: Review

References (95)

1. Taylor, C.P. Gabapentin. Mechanisms of action. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 321-34.
2. Dougherty, J.A., Rhoney, D.H. Gabapentin: A unique anti-epileptic agent. Neurol Res 2001, 23(8): 821-9.
3. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007, 73(2): 137-150.
4. Owen, R.T. Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today 2007, 43(9): 601-10.
5. Morris, G.L. Gabapentin. Epilepsia 1999, 40(Suppl. 5): S63-70.
6. Gu, Y., Huang, L.Y. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neurosci Lett 2002, 324(3): 177-80.
7. Suárez, L.M., Suárez, F., Del Olmo. N. et al. Presynaptic NMDA autoreceptors facilitate axon excitability: A new molecular target for the anticonvulsant gabapentin. Eur J Neurosci 2005, 21(1): 197-209.
8. Leach, J.P., Sills, G.J., Butler, E., Forrest, G., Thompson, G.G., Brodie, M.J. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res 1997, 27(3): 175-80.
9. Maneuf, Y.P., McKnight, A.T. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001, 134(2): 237-40.
10. Fink, K., Meder, W., Dooley, D.J., Göthert, M. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000, 130(4): 900-6.
11. Stringer, J.L., Taylor, C.P. Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 2007, 28: 75-82.
12. Wamil, A.W., McLean, M.J. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 1994, 17(1): 1-11.
13. Martin, D.J., McClelland, D., Herd, M.B. et al. Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropharmacology 2002, 42(3): 353-66.
14. Gee, N.S., Brown, J.P., Dissanayake, V.U., Offord, J., Thurlow, R., Woodruff, G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996, 271(10): 5768-76.
15. Wang, M., Offord, J., Oxender, D.L., Su, T.-Z. Structural requirement of the calcium channel subunit α2δ for gabapentin binding. Biochem J 1999, 342(Pt. 2): 313-20.
16. van Hooft, J.A., Dougherty, J.J., Endeman, D., Nichols, R.A., Wadman, W.J. Gabapentin inhibits presynaptic Ca2+ influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002, 449(3): 221-8.
17. Bayer, K., Ahmadi, S., Zeilhofer, H.U. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 2004, 46(5): 743-9.
18. Taylor, C.P. The biology and pharmacology of α2-δ proteins. CNS Drug Rev 2004, 10(2): 183-8.
19. Brown, J.T., Randall, A. Gabapentin fails to alter P/Q-type Ca2+ channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 2005, 55(4): 262-9.
20. Vajda, F.J.E. Gabapentin. Chemistry, biotransformation, pharmacokinetics, and interactions. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 335-9.
21. McLean, M.J. Gabapentin. Epilepsia 1995, 36(Suppl. 2): S73-86.
22. Perucca, E., French, J., Bialer, M. Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol 2007, 6(9): 793-804.
23. Schmidt, B. Gabapentin. Clinical efficacy and use in other neurological disorders. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 344-8.
24. Marson, A.G., Chadwick, D.W. Gabapentin. Clinical use. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 340-3.
25. Parke-Davis. Data on file. Morris Plains, New Jersey 1993.
26. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990, 335(8698): 1114-17.
27. Sivenius, J., Kalviainen, R., Ylinen, A., Riekkinen, P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991, 32(4): 539-42.
28. US Gabapentin Study Group. No 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology 1993, 43: 2292-8.
29. Anhut, H., Ashman, P., Feuerstein, T.J., Sauermann, W., Saunders, M., Schmidt, B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994, 35(4): 795-801.
30. Appleton, R., Fichtner, K., LaMoreaux, L., Alexander, J., Halsall, G., Murray, G., Garofalo, E. Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999, 40(8): 1147-54.
31. Marson, A.G., Kadir, Z.A., Hutton, J.L., Chadwick, D.W. Gabapentin for drug-resistant epilepsy. Cochrane Database Syst Rev 2000, 2: CD001415.
32. Yamauchi, T., Kaneko, S., Yagi, K., Sase, S. Treatment of partial seizures with gabapentin: Double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 2006, 60(4): 507-15.
33. Morrell, M.J., McLean, M.J., Willmore, L.J. et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure 2000, 9(4): 241-8.
34. Bruni, J. Neurontin as first add-on therapy in epileptic patients with partial seizures: Long term follow-up. Can J Neurol Sci 1998, 25(2): 134-40.
35. French, J.A., Kanner, A.M., Bautista, J. et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62(8): 1261-73.
36. Bergey, G.K., Morris, H.H., Rosenfeld. W. et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 1997, 49(3): 739-45.
37. Beydoun, A., Fischer, J., Labar, D.R. et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997, 49(3): 746-52.
38. Chadwick, D.W., Anhut, H., Greiner, M.J. et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998, 51(5): 1282-8.
39. Rowan, A.J., Ramsay, R.E., Collins, J.F. et al. New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64(11): 1868-73.
40. French, J.A., Kanner, A.M., Bautista, J. et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62(8): 1252-60.
41. Marson, A.G., Al-Kharusi, A.M., Alwaidh, M. et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet 2007, 369(9566): 1000-15.
42. Chadwick, D., Leiderman, D.B., Sauermann, W., Alexander, J., Garofalo, E. Gabapentin in generalized seizures. Epilepsy Res 1996, 25(3): 191-7.
43. Trudeau, V., Myers, S., LaMoreaux, L., Anhut, H., Garofalo, E., Ebersole, J. Gabapentin in naive childhood absence epilepsy: Results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996, 11(6): 470-5.
44. Wiffen, P.J., McQuay, H.J., Edwards, J.E., Moore, R.A. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005, 3: CD005452.
45. Mathiesen, O., Møiniche, S., Dahl, J.B. Gabapentin and postoperative pain: A qualitative and quantitative systematic review, with focus on procedure. BMC Anesthesiol 2007, 7: 6.
46. Gilron, I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: Current evidence and future directions. Curr Opin Anaesthesiol 2007, 20(5): 456-72.
47. Ho, K.Y., Gan, T.J., Habib, A.S. Gabapentin and postoperative pain-A systematic review of randomized controlled trials. Pain 2006, 126(1-3): 91-101.
48. Field, M.J., Li, Z., Schwarz, J.B. Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain. J Med Chem 2007, 50(11): 2569-75.
49. Li, C.Y., Zhang, X.L., Matthews, E.A. et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006, 125(1-2): 20-34.
50. Pan, H.L., Eisenach, J.C., Chen, S.R. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999, 288(3): 1026-30.
51. Hunter, J.C., Gogas, K.R., Hedley, L.R., Jacobson, L.O., Kassotakis, L., Thompson, J., Fontana, D.J. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997, 324(2-3): 153-60.
52. Kazi, J.A., Gee, C.F. Effect of gabapentin on c-Fos expression in the CNS after paw surgery in rats. J Mol Neurosci 2007, 32(3): 228-34.
53. Backonja, M., Beydoun, A., Edwards, K.R. et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998, 280(21): 1831-6.
54. Gorson, K.C., Schott, C., Herman, R., Ropper, A.H., Rand, W.M. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66(2): 251-2.
55. Chong, M.S., Hester, J. Diabetic painful neuropathy: Current and future treatment options. Drugs 2007, 67(4): 569-85.
56. Rowbotham, M., Harden, N., Stacey, B., Bernstein, P., Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998, 280(21): 1837-42.
57. Rice, A.S., Maton, S., Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001, 94(2): 215-24.
58. Matthews, E.A., Dickenson, A.H. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 2002, 96(3): 633-40.
59. Hahn, K., Arendt, G., Braun. J.S. et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004, 251(10): 1260-6.
60. Kimos, P., Biggs, C., Mah, J. et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: A randomized controlled trial. Pain 2007, 127(1-2): 151-60.
61. Mack, A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003, 9(6): 559-68.
62. Serpell, M.G, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain 2002, 99(3): 557-66.
63. Caraceni, A., Zecca, E., Bonezzi, C. et al. Gabapentin for neuropathic cancer pain: A randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004, 22(14): 2909-17.
64. Rao, R.D., Michalak, J.C., Sloan, J.A. et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110(9): 2110-8.
65. Cutter, N.C., Scott, D.D., Johnson, J.C., Whiteneck, G. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000, 81(2): 164-69.
66. Solaro, C., Lunari, G.L., Capello, E. et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998, 51(2): 609-11.
67. Happe, S., Klösch, G., Saletu, B., Zeitlhofer, J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001, 57(9): 1717-79.
68. Garcia-Borreguero, D., Larrosa, O., de la Llave, Y., Verger, K., Masramon, X., Hernandez, G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology 2002, 59(10): 1573-9.
69. Faulkner, M.A., Bertoni, J.M., Lenz, T.L. Gabapentin for the treatment of tremor. Ann Pharmacother 2003, 37(2): 282-6.
70. Pahwa, R., Lyons, K., Hubble, J.P. et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998, 13(3): 465-7.
71. Ondo, W., Hunter, C., Vuong, K.D., Schwartz, K., Jankovic, J. Gabapentin for essential tremor: A multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000, 15(4): 678-82.
72. di Trapani, G., Mei, D., Marra, C. et al. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo controlled study. Clin Ter 2000, 151(3): 145-8.
73. Spira, P.J., Beran, R.G., and the Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controlled study. Neurology 2003, 61(12): 1753-9.
74. Miller, R.G., Moore, D., Young, L.A. et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996, 47(6): 1383-8.
75. Merlini, L., Solari, A., Vita, G. et al. Role of gabapentin in spinal muscular atrophy: Results of a multicenter, randomized Italian study. J Child Neurol 2003, 18(8): 537-41.
76. Greist, J.H. Gabapentin. Clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 349-53.
77. Pande, A.C., Davidson, J.R., Jefferson, J.W. et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999, 19(4): 341-8.
78. Pande, A.C., Crockatt, J.G., Janney, C.A., Werth, J.L., Tsaroucha, G. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000, 2(3, Pt. 2): 249-55.
79. Vieta, E., Manuel Goikolea, J., Martinez-Aran, A. et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006, 67(3): 473-7.
80. McLean, R., Proudlock, F., Thomas, S., Degg, C., Gottlob, I. Congenital nystagmus: Randomized, controlled, double-masked trial of memantine/gabapentin. Ann Neurol 2007, 61(2): 130-8.
81. Lee, K.J., Kim, J.H., Cho, S.W. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22(10): 981-8.
82. Arnold, L.M., Goldenberg, D.L., Stanford, S.B. et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56(4): 1336-44.
83. Pandya, K.J., Morrow, G.R., Roscoe, J.A. et al. Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 2005, 366(9488): 818-24.
84. Reddy, S.Y., Warner, H., Guttuso, T. et al. Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. Obstet Gynecol 2006, 108(1): 41-8.
85. Ramsay, E.R., Pryor, F.M. Gabapentin. Adverse effects. In: Antiepileptic Drugs, 5th Edition. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.). Lippincott Williams & Wilkins: Philadelphia 2002, 354-359.
86. Asconape, J., Diedrich, A., Dellabadia, J. Myoclonus associated with the use of gabapentin. Epilepsia 2001, 41(4): 479-81.
87. Striano, P., Coppola, A., Madia, F. et al. Life-threatening status epilepticus following gabapentin administration in a patient with benign adult familial myoclonic epilepsy. Epilepsia 2007, 48(10): 1995-8.
88. Aldenkamp, A.P. Effects of antiepileptic drugs on cognition. Epilepsia 2001, 42(Suppl. 1): 46-9.
89. Ortinski, P., Meador, K.J. Cognitive side effects of antiepileptic drugs. Epilepsy Behav 2004, 5(Suppl. 1): S60-5.
90. Leach, J.P., Girvan, J., Paul, A., Brodie, M.J. Gabapentin and cognition: A double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997, 62(4): 372-6.
91. Dodrill, C., Arnett, J., Hayes, A. et al. Cognitive abilities and adjustement with gabapentin: Results of a multisite study. Epilepsy Res 1999, 35(2): 109-21.
92. Martin, R., Kuzniecky, R., Ho, S. et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999, 52(2): 321-7.
93. Wong, M.O., Eldon, M.A., Keane, W.E. et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995, 35(6): 622-6.
94. Hughes, D., Cockerell, O.C. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996, 5(2): 89-95.
95. Morello, C.M., Leckband, S.G., Stoner, C.P., Moorhouse, D.F., Sahagian, G.A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999, 159(16): 1931-7.